Skip to main content
. 2022 Sep 21;13(9):808. doi: 10.1038/s41419-022-05242-5

Fig. 6. Rimonabant combined with erastin/RSL3 significantly repressed TNBC tumor growth in vivo.

Fig. 6

A Treatment schedule for the MDA-MB-231 cells orthotopic implantation model was treated with vehicle, rimonabant (SR), erastin and RSL3 as single agents or drug combinations. B–D Mice were treated as (A) 12 days after xenograft, and tumor size was monitored every other day B. Photograph of tumors (C) and tumor weight (D) are shown (n = 6 per group). **p < 0.01 (one-way ANOVA). E Body weight of BALB/c nude mice treated as (A) were shown (n = 6 per group). F Survival rates for nude mice treated as in (A) were shown (log-rank test; n = 6 per group). **p < 0.01 (Kaplan–Meier). G Representative images of H&E, Ki-67 and 4-HNE IHC staining in harvested tumors from each group were shown. Scale bars represent 50 mm. H WB analysis of SCD1 and FADS2 in harvested tumors from each group were shown. I Proposed model for CB1 regulated SCD1- and FADS2-dependent fatty acid metabolism via PI3K-AKT and MAPK signaling pathways to inhibit TNBC cell growth. Data shown are the means ± SD from six tumors at each time point.